Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter randomized double-blind placebo-controlled study of CMS-D002 capsules for uterine fibroids with menorrhagia
ChiCTR2500112323Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CMS-D002 in Fibromyoma (LM) and menstrual disorders (4 arms), sponsored by Peking University First Hospital. Primary endpoint: Proportion of participants with reduced menstrual bleeding at 12 weeks of treatment. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CMS-D002
03
Conditions
Fibromyoma (LM)menstrual disorders
Beyond the preview
Go deeper on ChiCTR2500112323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112323.